Aurobindo Pharma steady as analysts watch numbers for near-term growth

The company's investments across segments will take at least two years to play out, say analysts

Aurobindo Pharma’s December-quarter results were largely in line with the Street estimates, given that growth was driven by the antiretroviral segment and the US business. While its injectables portfolio was steady, sales in the US market, which accounts for over half of its turnover, were driven by the oral portfolio. The disappointment was on account of muted revenues of active pharmaceutical ingredients (APIs), which were down 14 per cent over the year-ago quarter.

While sales were up 8 per cent and gross margins also expanded by 310 basis points over the year-ago quarter, the increase in operating profit margins was limited